BPC-157 is a research peptide that is not FDA-approved for any medical use. The FDA issued guidance in 2023 placing BPC-157 on a list of substances that cannot be used in compounded medications. Clinics that previously offered BPC-157 as a compounded peptide have largely stopped or shifted to alternative peptides. Its legal status for clinical use is effectively restricted in the United States.
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in gastric juice. It has shown promising results in animal studies for tissue healing, gut repair, and inflammation — but it has never been through FDA-approved human clinical trials.
Until recently, BPC-157 was available through compounding pharmacies as a research peptide and was widely prescribed by clinics for injury recovery, gut healing, and general tissue repair. However, the FDA’s 2023 guidance on compounding pharmacies specifically named BPC-157 as a substance that does not meet the criteria for use in compounded medications.
This means that licensed clinics in the US can no longer legally prescribe BPC-157 through regulated compounding pharmacies. Some clinics may still reference it in educational materials or discuss it as a research compound, but prescribing it for patient use is not compliant with current FDA guidance.
Alternative peptides that remain available through compounding pharmacies for similar purposes include TB-500 (thymosin beta-4), pentosan polysulfate, and others — though the regulatory landscape for peptides continues to evolve.
Patients interested in peptide therapy should work with a provider who stays current on which compounds are legally available through regulated compounding pharmacies.